Satellos Bioscience has taken a significant step forward by filing an Investigational New Drug application with the FDA to advance its Phase 2 trial of SAT-3247 for degenerative muscle diseases. This move not only underscores the company’s commitment to addressing critical medical needs but also positions it strategically in the competitive biotechnology landscape.
TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambul
Source: Original Press Release
